The diaminoquinazoline series has good potency against Mycobacterium tuberculosis. 17
lead like compounds for anticancer and antimalarial drug discovery programs (1, 2) . A 31 high throughput screening campaign led to the discovery of a series of 32 diaminoquinazoline (DAQ) compounds that was active against Mycobacterium 33 tuberculosis with minimum inhibitory concentrations (MIC) in the sub-micromolar range 34
(3). We carried out a structure activity relationship analysis to evaluate the potential of 35 the DAQ series and identified a number of analogs with improved anti-tubercular activity 36 and good exposure in rat pharmacokinetic studies (4) . DAQ compounds had 37 bactericidal activity against replicating and non-replicating bacteria (4) . The target for 38 the DAQ series is not known, but DAQ-resistant isolates have mutations in Rv3161c, a 39 putative dioxygenase (4) . Since Rv3161c is not essential, and we predict that the 40 mutation would lead to reduced or lower activity, it is unlikely that this is the intracellular 41 target of the series. 42 43 Rv3161c is highly induced in M. tuberculosis treated with benzene-containing 44 compounds such as thioridazine, SRI#967, SRI#9190 and triclosan (5-7). However, 45 triclosan was equally active against wild-type and Rv3161c deletion strains of M. 46 tuberculosis. In addition, strains which over-expressed Rv3161c did not demonstrate triclosan resistance, suggesting it is not involved in mediating resistance (5). 48
49
We hypothesize that DAQ compounds are prodrugs activated by Rv3161c. In order to 50 assess this hypothesis we wanted to determine if DAQ molecules were transformed 51 after uptake by M. tuberculosis. In our previous work, we had only determined the MIC 52 on solid medium using the serial proportion method (8). For compound IDR-0010006, 53 the MIC 99 for wild-type was 6.25 µM, but for the resistant mutants was 25 µM (a 4-fold 54 shift) (4) . In order to run metabolite identification studies, we determined the MICs for 55 the wild-type and resistant strains in Middlebrook 7H9 liquid medium supplemented with 56 10% v/v OADC (oleic acid, albumin, dextrose, catalase) and 0.05% w/v Tween 80. 57
Compounds were tested as a 10-point, 2-fold serial dilution in 96-well plates as 58 described (9)(8). Growth was measured after 5 days at 37°C and the % growth 59 calculated with respect to controls. Curves were fitted using the Levenberg-Marquardt 60 algorithm and IC 90 calculated as the concentration of compound required to inhibit 61 growth by 90%. We determined IC 90 s for IDR-0010006 and IDR-0258237 against wild-62 type and the mutants strain containing the all Rv3161c C115W allele ( Table 1 ). Both 63 compounds were 2.5-fold less active against the mutant strain as compared to wild-64 type, which is comparable to the shift seen on solid medium. 65
66
Once we had established liquid IC 90 , we carried out metabolite analysis using 67 compound IDR-0258237. We first established the settings required to detect the parent 68 compound. LC-MS was carried out on using an Agilent 1100 HPLC and G1956B 69 LC/MSD SL mass spectrometer set in positive mode with simultaneous UV-vis detection 70 at 214 and 254 nm. Buffer A was 0.05% formic acid in water and Buffer B was 0.05% 71 formic acid in acetonitrile. The following solvent gradient was used (time, % Buffer B): 0 72 min, 10%; 30 min, 6.3 min, 95%; 8.1 min, 95%; 8.4 min, 10%; and 10.5 min, 10%. 73
Under these conditions, compound IDR-0258237 eluted at ~4.5 min with a m/z value of 74 compound ( Fig 1A) . 76 77 Next, we treated wild-type and mutant strains with compound IDR-0258237. M. 78 tuberculosis cultures were grown in 100 mL of 7H9-Tw-OADC in 450 cm 2 roller bottles 79 at 100 rpm for 5 days at 37°C.Compound IDR-0258237 was added at 20 µM for 24 h or 80 48h; DMSO was used as a negative control. Cells were harvested by centrifugation, 81 extracted with an equal volume of 1:1 chloroform-methanol and incubated at 55 o C for 82 30 min. Samples were re-extracted with 1:1 chloroform-methanol and the two extracts 83 pooled. The volume was adjusted to 5 mL with 1:1 chloroform-methanol and refluxed for 84 16-24 hr. Pellets were extracted with chloroform, dried, resuspended in 1:1 85 acetonitrile:water and subjected to LC-MS analysis (Fig 1 and Fig 2) . 86
87
In the wild-type strain, we did not see a peak corresponding to IDR-0258237 in the total 88 ion chromatogram (TIC) ( Fig 1B) . In contrast, a peak consistent with IDR-0258237 was 89 observed in extracts from the mutant strain ( Fig 1B) . Similar results were observed after 90 48 h of incubation ( Fig 1D and 1E) . 91 92 Rv3161c is a putative dioxygenase, which could catalyze the incorporation of two 93 oxygen atoms into the substrate. Alternatively, it could function as a monooxygenase 94 and catalyze the introduction of a single oxygen atom. We extracted the ion masses of 95 all potential mono-hydroxylated and di-hydroxylated products from the TIC from all 96 samples (Fig 2) . An ion (1) with a retention time of ~4.1 min and m/z of 354, was 97 observed in the wild-type extracts, but not in any of the controls or in the Rv3161c 98 mutant extracts (Fig. 2) . The MS properties of this ion are consistent with the addition of 99 one water molecule across the heteroaromatic ring system resulting in the mono-100 hydroxylation of N1 (mono-hydroxylated DAQ) (Fig. 3) . Alternatively, an epoxidation will 101 also give the observed ion with an exact mass of 354. We did not detect any other 102 mono-hydroxylated, di-hydroxylated or cleaved aromatic ring derivatives. LC/MS-MS 103 experiments would be needed for metabolite ID and confirmation. These results are 104 consistent with Rv3161c catalyzing the modification of DAQ compounds into a 105 metabolite that is active against M. tuberculosis. 106
107
Mutation of Rv3161c only led to low level resistance, although the mutant strain did not 108 appear to metabolize the DAQ compound to any detectable extent. This suggests that 109 both the parent molecule and the metabolite are active, but that the metabolite has 110 greater activity against the unknown target. We attempted to synthesize analogs 111 incorporating the predicted hydroxylation, but we were not successful. Therefore, a full 112 characterization of the metabolite(s) and its activity would require a large scale 113 purification directly from M. tuberculosis. 114
115
In conclusion, we have determined that a member of the DAQ series is metabolized by 116 wild-type M. tuberculosis, but not by a strain containing a mutation in Rv3161c. These 117 data support our hypothesis that the DAQ compounds are biotransformed to more 118 active compounds within the bacterial cell. 
